Search

Displaying results 6411 - 6420 of 8696 in total
  1. Drug

    Centhaquine

    go.drugbank.com/drugs/DB16122
    Investigational

    Centhaquine is under investigation in clinical trial NCT04045327 (Efficacy of PMZ-2010 (Centhaquine) a Resuscitative Agent for Hypovolemic Shock).

  2. Drug

    Fasedienol

    go.drugbank.com/drugs/DB04968
    Investigational

    PH94B is being developed by Pherin Pharmaceuticals, Inc. for the treatment of social phobias (generalized anxiety disorder).

  3. Drug

    Amitraz

    go.drugbank.com/drugs/DB11373
    ExperimentalVet approved

    Amitraz presents insect repellent effects and hence, it can be used as an insecticide and pesticide.

    Categories: Adrenergic alpha-2 Receptor Agonists
  4. Drug

    BG-777

    go.drugbank.com/drugs/DB05839
    Experimental

    BG-777 is an immunomodulator with proven efficacy against viral and bacterial infections in preclinical studies.

  5. Drug

    Fludiazepam

    go.drugbank.com/drugs/DB01567
    IllicitInvestigational

    It is a scheduled drug in the U.S., but is approved for use in Japan.

  6. Drug

    BRD-810

    go.drugbank.com/drugs/DB23607
    Experimental

    BRD-810 is an experimental small molecule being investigated as a potential anti-cancer medication. It is an inhibitor of the protein myeloid cell leukemia 1 (MCL1). [A274263]

  7. Drug

    PS386113

    go.drugbank.com/drugs/DB05211
    Experimental

    PS386113 is a small molecule drug candidate under investigation for the treatment of inflammatory disorders. It is being developed by Schering-Plough and Pharmacopeia.

  8. Drug

    TW-37

    go.drugbank.com/drugs/DB17059
    Experimental

    TW-37 is a small-molecule inhibitor of Bcl-2 investigated for its anti-cancer properties.[A253157]

  9. Drug

    BHT-3034

    go.drugbank.com/drugs/DB18045
    Experimental

    BHT-3034 is a DNA plasmid vaccine immunotherapy under investigation for the treatment of myasthenia gravis.[L48086]

  10. Drug

    XEN-D0501

    go.drugbank.com/drugs/DB18673
    Investigational

    XEN-D0501 is a tetrahydronaphthyl urea-based selective TRPV1 antagonist being investigated for the treatment of erythromelalgia.